866207-70-7

Usage

Uses

Used in Pharmaceutical Industry:
(E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a valuable building block for the development of new drugs, potentially contributing to the treatment of various medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, (E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol is utilized as a key component in the production of agrochemicals. Its incorporation into these products can enhance their effectiveness in protecting crops from pests and diseases, thereby increasing agricultural productivity.
Used in Organic Synthesis:
(E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol serves as a versatile building block in organic synthesis, allowing for the creation of a wide range of organic compounds. Its unique structure and reactivity make it a valuable asset in the development of new chemical products, including those with potential applications in various industries such as materials science, electronics, and more.

Upstream product

• 866207-69-4 (E)-ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate 
• 659-28-9 p-trifluoromethoxybenzaldehyde 

Downstream Products

• 183800-94-4 trans-4-(trifluoromethoxy)cinnamaldehyde 
• 1333170-27-6 (6S)-2-nitro-6-({(2E)-3-[4-trifluoromethoxyphenyl]-2-propenyl}oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333171-36-0 1-[(1E)-3-bromo-1-propenyl]-4-trifluoromethoxybenzene 

Relevant academic research and scientific papers

Synthesis of Allylsilanes via Nickel-Catalyzed Cross-Coupling of Silicon Nucleophiles with Allyl Alcohols

NiCl2(PMe3)2-catalyzed reaction of allyl alcohols with silylzinc reagents, including PhMe2SiZnCl, Ph2MeSiZnCl, and Ph3SiZnCl, was performed, achieving allylsilanes in high yields. Aryl- and heteroaryl-substituted allyl alcohols, (E)-3-arylprop-2-en-1-ols, 1-aryl-prop-2-en-1-ols, and (E)-1-phenylpent-1-en-3-ol can be employed in the transformation. A range of functional groups as well as heteroaryl groups were tolerated. Reaction exhibited high regioselectivity and E/Z-selectivity when 1- or 3-aryl-substituted allyl alcohols were used as the substrates. Reaction of chiral allyl alcohol, (S,E)-1-phenylpent-1-en-3-ol, yielded a configuration-inversion product (R,E)-dimethyl(phenyl)(1-phenylpent-1-en-3-yl)silane.

FUROXANS AS THERAPIES FOR NEURODEGENERATIVE DISORDERS

Furoxan compounds, compositions comprising the same, and methods of making and using the same, are described.

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Synthesis and antifungal activities of R-102557 and related dioxane- triazole derivatives

Novel triazole compounds with a dioxane ring were synthesized. Condensation of the diol precursor 10 with various aromatic aldehydes 11 - 13 under acidic conditions afforded a series of dioxane-triazole compounds 14 - 16. The antifungal activities of the compounds 14 - 16 were evaluated in vivo in mice infection models against Candida and Aspergillus species. High activities were seen for the derivatives with one or two double bond(s) and an aromatic ring substituted with an electron-withdrawing group in the side chain. Among the derivatives, R-102557 (16R: Ar=4-(2,2,3,3- tetrafluoropropoxy)phenyl) showed excellent in vivo activities against Candida, Aspergillus and Cryptococcus species. It also showed high tolerance in a preliminary toxicity study in rats.